MIAMI, April 08, 2026 (GLOBE NEWSWIRE)-- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic ...
Yet, despite its promise, CAR T-cell immunotherapy still faces challenges that limit its widespread clinical adoption. One key issue is that T cells often become exhausted during their lab-based ...
Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results